Inovio Pharmaceuticals (INO) Q4 2024 earnings summary

Executive summary

• Advanced INO-3107 for recurrent respiratory papillomatosis (RRP), resolving CELLECTRA device manufacturing issues and preparing for BLA submission in 2025, with commercial launch readiness and pipeline progress including INO-3112 and DMAb technology.

• INO-3107 demonstrated durable efficacy, with 50% complete response at year two, >75% reduction in surgeries over three years, and strong immunology data supporting its mechanism.

• Commercial preparations include distribution strategy, pricing research, organizational build-out, and targeting a concentrated RRP market.

• Advanced pipeline with Phase 3 planning for INO-3112 in HPV-positive throat cancer, Phase 2 plans for INO-4201 as Ebola booster, and ongoing development for INO-5401 and INO-3100.

• DMAb technology showed durable in vivo antibody production, no anti-drug antibodies, and favorable safety profile in Phase I COVID-19 trial.

Financial highlights

• Raised over $72 million in gross proceeds from equity offerings and ATM sales in 2024.

• Operating expenses decreased 22% year-over-year to $112.6 million in 2024.

• Net loss for 2024 was $107.3 million ($3.95/share), improved from $135.1 million ($6.09/share) in 2023.

• Ended 2024 with $94.1 million in cash, cash equivalents, and short-term investments, projecting runway into Q1 2026.

• Total revenues were $218,000 for 2024, compared to $832,000 in 2023.

Outlook and guidance

• Plan to begin rolling BLA submission for INO-3107 in mid-2025, aiming for FDA acceptance by year-end 2025 and potential commercial launch if approved.

• Confirmatory Phase III trial for INO-3107 to be initiated before BLA submission; most sites identified and IRB approvals in place.

• Cash runway expected to support operations into Q1 2026, excluding further capital raises.

• Operational net cash burn estimated at ~$27 million for Q1 2025.

• Continued advancement of DMAb and other pipeline programs, with further updates expected.